country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P991001

Copy Link Print Information

Biologically Validated

Imzokitug

Name: Imzokitug
Brand: MedChemExpress
SKU: HY-P991001
Price: 350.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: BMS-986340; CCR8.50)

Kundenbewertung

Based on 1 Customer Validation

Imzokitug (BMS-986340; CCR8.50) is a CCR8 binding agent. Imzokitug inhibits tumor growth in syngeneic tumors by blocking CCR8 and depleting tumor-resident CCR8⁺ Treg cells, while increasing CD4⁺/CD8⁺ T cell proliferation and upregulating PD-1. Imzokitug can be used for cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98%
CAS. Nr.: 2883771-61-5
Molecular Weight:145.863 kDa

Speicherung:

Shipping with dry ice

Please store the product under the recommended conditions in the Certificate of Analysis.

Imzokitug Chemical Structure

CAS. Nr.: 2883771-61-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconstitution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

^[1]

CCR8

Alle CCR Isoform-spezifische Produkte anzeigen :

In Vitro

Adaptive ImmunityImmune Tolerance & ImmunosuppressionAnti-cancer

Adaptive Immunity

Immune Tolerance & Immunosuppression

Anti-cancer

Imzokitug (BMS-986340; CCR8.50) depletes CCR8⁺ tumor-infiltrating regulatory T cells in human tumor explants^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-cancerAdaptive ImmunityImmune Tolerance & Immunosuppression

Anti-cancer

Adaptive Immunity

Immune Tolerance & Immunosuppression

Imzokitug (BMS-986340; CCR8.50) (2-10 mg/kg; i.p.; repeated administration at least 6 times) produces dose-related tumor growth inhibition in MC38 syngeneic tumors in hCCR8 (v2) knock-in C57BL/6 mice, with TGI of approximately 38% at 2 mg/kg and approximately 50% at 10 mg/kg, and reduces tumor-resident CCR8⁺ Tregs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (hCCR8 (v2) knockin expressing full-length human CCR8)^[2]
Dosage:

2 mg/kg; 10 mg/kg
Administration:

i.p.; repeated dosing to at least 6 doses
Result:

Led to ~38% TGI at 2 mg/kg and ~50% TGI at 10 mg/kg in the MC38 tumor model.
Tumor-resident CCR8⁺ Treg populations decreased, and CD4⁺/CD8⁺ T cell proliferation and PD-1 upregulation in CD4⁺/CD8⁺ T cells were observed 24 h post 6th dose.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Gene ID

1237 [NCBI]

Accession

P51685

Conjugated

Unconjugated

Reconstitution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG1-kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Flow Cytometry analysis of Raji cells labelling CCR8 (red) with Imzokitug (HY-P991001). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Chemical Information

CAS. Nr. 2883771-61-5
Appearance Liquid
Molecular Weight 145.863 kDa
Color Colorless to light yellow
SMILES

[Imzokitug]
Synonyms

BMS-986340; CCR8.50
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Lan R, et al. Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models[J]. Cancer Research, 2020, 80(16_Supplement): 6694-6694.

[2]. Li Y, et al. 10 Enhancing the therapeutic responses of anti-human CCR8 mAbs utilizing the fully humanized CCR8 knockin mice. Journal for ImmunoTherapy of Cancer. 2023;11:.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconstitution
- Format
- Anwendung
- Biological Activity
Chemical Information
Reinheit & Dokumentation
Verweise

1/16

IgG1-kappa
1/16

Flow Cytometry analysis of Raji cells labelling CCR8 (red) with Imzokitug (HY-P991001). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
1/16

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Imzokitug

Alle CCR Isoform-spezifische Produkte anzeigen